- $1.22bn
- $1.17bn
- $30.91m
Brief: Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
U.S. RESEARCH ROUNDUP- Carnival, Jll, Microsoft
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
Brief: Verastem Files Prospectus Related To Resale From Time To Time Of Up To 1.4 Million Shares Of Common Stock By Selling Stockholders
Brief: Verastem Q4 Basic EPS USD -1.33
Verastem Inc reports results for the quarter ended December 31 - Earnings Summary
Verastem Inc expected to post a loss of 81 cents a share - Earnings Preview
Verastem Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women’s Cancer
Brief: Verastem Oncology Names Matthew E. Ros As Chief Operating Officer
Brief: Verastem Oncology Exercises Option Early to License VS-7375
Brief: Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Comm services, Nvidia, US insurers
U.S. STOCKS ON THE MOVE-Boeing, US banks, Flagstar Financial
Verastem jumps as FDA grants priority review for ovarian cancer combo therapy
U.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa
Brief: Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Brief: Applied Therapeutics Appoints John H. Johnson As Executive Chairman